Anna Maria Piccinini

Dr. Anna Maria Piccinini

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2009 in Nature Medicine
Verified
Journal Article
Closed access
KMKim Midwood
Kim Midwood
SSSandra Sacre
Sandra Sacre
APAnna Maria Piccinini
Anna Maria Piccinini
JIJulia Inglis
Julia Inglis
ATAnnette Trebaul
Annette Trebaul
BFBrian Foxwell
Brian Foxwell

4 January 2009 in Nature Medicine
Verified
Journal Article
Closed access
RKRory Ryan Koenen
Rory Ryan Koenen
PHPhilipp von Hundelshausen
Philipp von Hundelshausen
Irina NesmelovaIrina Nesmelova
Irina Nesmelova
AZAlma Zernecke
Alma Zernecke
ELElisa A. Liehn
Elisa A. Liehn
CWChristian Weber
Christian Weber

16 June 2018 in Immunology
Verified
Journal Article
Closed access
PDF file
HTHannah Tomlin
Hannah Tomlin
APAnna Maria Piccinini
Anna Maria Piccinini

1 March 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
FGFui G. Goh
Fui G. Goh
APAnna Maria Piccinini
Anna Maria Piccinini
TKThomas Krausgruber
Thomas Krausgruber
IUIrina A Udalova
Irina A Udalova
KMKim S. Midwood
Kim S. Midwood
Inappropriate expression of proinflammatory mediators underpins the pathogenesis of autoimmune disease and tumor metastasis. The extracellular matrix glycoprotein tenascin-C is an endogenous activator of innate immunity that promotes the synthesis of inflammatory cytokines via activation of TLR4. Little tenascin-C is observed in most healthy adult tissues, but expression is specifically upregulated at sites of inflammation. Moreover, high levels of tenascin-C are associated with chronic inflammation and found in the tumor stroma. In this study, we show that the expression of tenascin-C is induced in immune myeloid cells activated by a variety of inflammatory stimuli, including specific TLR ligands. Its synthesis is transcriptionally regulated and requires the specific activation of AKT/PI3K and NF-κB signaling pathways. Using a bioinformatic approach, we identified a large number of conserved noncoding regions throughout the tenascin-C genomic locus that may contribute to its transcriptional regulation during inflammation. We also demonstrate that tenascin-C expression is transient during acute inflammation. In contrast, persistently high levels of expression occur in the inflamed synovium of joints from rheumatoid arthritis patients. Thus, misregulated expression of this endogenous danger signal may promote an autocrine loop of inflammation and contribute to the persistence of inflammation in autoimmune diseases or to tumor egress and invasion during metastasis.

21 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAlasdair G. Kay
Alasdair G. Kay
GLGrace Long
Grace Long
GTGeorge Tyler
George Tyler
ASAndrei Stefan
Andrei Stefan
SBStephen J. Broadfoot
Stephen J. Broadfoot
OKOksana Kehoe
Oksana Kehoe
We evaluated the therapeutic potential of mesenchymal stem cell-conditioned medium (CM-MSC) as an alternative to cell therapy in an antigen-induced model of arthritis (AIA). Disease severity and cartilage loss were evaluated by histopathological analysis of arthritic knee joints and immunostaining of aggrecan neoepitopes. Cell proliferation was assessed for activated and naïve CD4+ T cells from healthy mice following culture with CM-MSC or co-culture with MSCs. T cell polarization was analysed in CD4+ T cells isolated from spleens and lymph nodes of arthritic mice treated with CM-MSC or MSCs. CM-MSC treatment significantly reduced knee-joint swelling, histopathological signs of AIA, cartilage loss and suppressed TNFα induction. Proliferation of CD4+ cells from spleens of healthy mice was not affected by CM-MSC but reduced when cells were co-cultured with MSCs. In the presence of CM-MSC or MSCs, increases in IL-10 concentration were observed in culture medium. Finally, CD4+ T cells from arthritic mice treated with CM-MSC showed increases in FOXP3 and IL-4 expression and positively affected the Treg:Th17 balance in the tissue. CM-MSC treatment reduces cartilage damage and suppresses immune responses by reducing aggrecan cleavage, enhancing Treg function and adjusting the Treg:Th17 ratio. CM-MSC may provide an effective cell-free therapy for inflammatory arthritis.

17 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
LZLorena Zuliani-Alvarez
Lorena Zuliani-Alvarez
AMAnna M. Marzeda
Anna M. Marzeda
CDClaire Deligne
Claire Deligne
ASAnja Schwenzer
Anja Schwenzer
FMFiona E. McCann
Fiona E. McCann
KMKim S. Midwood
Kim S. Midwood
Pattern recognition underpins innate immunity; the accurate identification of danger, including infection, injury, or tumor, is key to an appropriately targeted immune response. Pathogen detection is increasingly well defined mechanistically, but the discrimination of endogenous inflammatory triggers remains unclear. Tenascin-C, a matrix protein induced upon tissue damage and expressed by tumors, activates toll-like receptor 4 (TLR4)-mediated sterile inflammation. Here we map three sites within tenascin-C that directly and cooperatively interact with TLR4. We also identify a conserved inflammatory epitope in related proteins from diverse families, and demonstrate that its presence targets molecules for TLR detection, while its absence enables escape of innate immune surveillance. These data reveal a unique molecular code that defines endogenous proteins as inflammatory stimuli by marking them for recognition by TLRs.